Doctors in New South Wales and Victoria Become First in Australia to Treat Patients with Aortic Aneurysms Using GORE® DrySeal Sheath

03 August 2010 (SYDNEY and FLAGSTAFF, Arizona)

Revolutionary Device Delivers Consistent Performance, Better Control, and Minimized Blood Loss During Minimally Invasive Endovascular Procedure

W.L. Gore & Associates (Gore) announced today the first clinical cases in Australia involving the revolutionary GORE® DrySeal Sheath. The sheath aids in minimally invasive treatment of patients with abdominal aortic aneurysms (AAA) utilizing the GORE® EXCLUDER® AAA Endoprosthesis and thoracic aortic aneurysms (TAA) utilizing the GORE® TAG® Thoracic Endoprosthesis.

The first successful procedures were performed by Thomas Daly, MD, at Westmead Hospital, New South Wales, Alan Bray, MD at Newcastle Private, New South Wales, and Michael Denton, MD, at Epworth Private Hospital, Victoria. According to Dr. Daly, who performed the first clinical case in Australia, during treatment of an emergent, symptomatic AAA, “The haemostasis achieved with the GORE DrySeal Sheath is unsurpassed by any other large diameter commercial sheath. Its versatility reduces patient blood loss while not compromising accessibility.”

The GORE DrySeal Sheath, which was recently released in Australia, is comprised of an innovative hemostatic valve attached to the introducer sheath. The valve is unique in that it is pressurized to create a seal, thereby minimizing blood loss and accommodating multiple wires and catheters simultaneously. The valve consists of a silicone outer tube and an inner film tube that create an effective hemostatic seal that easily adapts to the profiles of the inserted devices. The GORE DrySeal Sheath is available in profiles from 12 to 26 Fr, in 2 Fr increments, and has a working length of 28 cm.

Gore Aortic Business Leader David Abeyta added, “The GORE DrySeal Sheath is the newest addition to Gore’s world-class portfolio and is further evidence of Gore’s commitment to the development of innovative solutions to address unmet clinical needs in the Australian endovascular market.”


The Gore Medical Products Division has provided creative therapeutic solutions to complex medical problems for three decades. During that time, more than 25 million innovative Gore Medical Devices have been implanted, saving and improving the quality of lives worldwide. The extensive Gore Medical family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia repair, soft tissue reconstruction, staple line reinforcement and sutures for use in vascular, cardiac and general surgery. Gore was recently named one of the best companies to work for by Fortune magazine for the 13th consecutive year.